Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Product update

Side effects and interactions for Fareston

The summary of product characteristics (SPC) for Fareston (toremifene; Orion) now states that cases of liver injury, including elevation of liver enzymes, hepatitis and jaundice, have been reported with toremifene. Additionally, the amount of lactose per tablet has been amended from 30mg to 28.5mg. The updated SPC also states that, theoretically, the metabolism of toremifene is inhibited by drugs known to inhibit the CYP3A enzyme system. Examples of such drugs are antifungal imidazoles, other antifungal agents, protease inhibitors and macrolides. Concomitant use of those drugs with toremifene should be carefully considered.


Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069314

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.